Long-term Antibody Persistence After Hepatitis E Virus Infection and Vaccination in Dongtai, China

Brittany L Kmush, Huan Yu, Shoujie Huang, Xuefang Zhang, Ting Wu, Kenrad E Nelson, Alain B Labrique, Brittany L Kmush, Huan Yu, Shoujie Huang, Xuefang Zhang, Ting Wu, Kenrad E Nelson, Alain B Labrique

Abstract

Background: Hepatitis E virus (HEV) is of global significance. HEV is a common cause of acute hepatitis in China. One of the major unanswered questions about HEV is the persistence of antibodies after infection and vaccination.

Methods: We examined antibody persistence 6.5 years after HEV exposures through natural infection and vaccination. Ninety-seven vaccine recipients and 70 individuals asymptomatically infected with HEV enrolled in the phase III HEV239 vaccine trial in Dongtai, China, were revisited.

Results: Antibody loss was 23.4% (95% confidence interval [CI], 17.1%-30.5%), with a nonsignificantly higher percentage of loss among those naturally infected (30.0%; 95% CI, 19.6%-42.1%) than those vaccinated (18.6%; 95% CI, 11.4%-27.7%; P = .085). Age and gender were not associated with antibody persistence. Only 2 people (1.2%) self-reported medically diagnosed jaundice or hepatitis-like illness in the last 10 years, both of whom had persistent antibodies. Contact with a jaundice patient and injectable contraceptive use were marginally associated with loss of detectable anti-HEV antibodies (P = .047 and .082, respectively), whereas transfusion was marginally associated with antibody persistence (P = .075).

Conclusions: Antibody loss was more common among those naturally infected compared with those vaccinated. However, none of the characteristics examined were strongly associated with antibody loss, suggesting that factors not yet identified may play a more important role in antibody loss. Long-term postvaccination antibody persistence is currently unknown and will be an important consideration in the development of policies for the use of the highly efficacious HEV vaccine. ClinicalTrials.gov registration. NCT01014845.

Keywords: antibody persistence; epidemiology; hepatitis E vaccine; hepatitis E virus.

Figures

Figure 1.
Figure 1.
Cohort selection and follow-up diagram. Abbreviation: HEV, hepatitis E virus.

References

    1. Dalton HR, Hazeldine S, Banks M, et al. . Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369:1260.
    1. Navaneethan U, Mohajer MA, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int 2008; 28:1190–9.
    1. Labrique AB, Kuniholm MH, Nelson KE. The global impact of hepatitis E: new horizons for an emerging virus. In: Scheld WM, Grayson ML, Hughes JM, eds. Emerging Infections Vol. 9 Washington, DC: ASM Press; 2010:53–93.
    1. Rein DB, Stevens G, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus. Hepatology 2012; 55:988–97.
    1. Lu J, Zhou Y, Lin X, et al. . General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4:e8467.
    1. Zhuang H, Cao XY, Liu CB, Wang GM. Epidemiology of hepatitis E in China. Gastroenterol Jpn 1991; 26(Suppl 3):135–8.
    1. Kmush B, Wierzba T, Krain L, Nelson K, Labrique AB. Epidemiology of hepatitis E in low- and middle-income countries of Asia and Africa. Semin Liver Dis 2013; 33:15–29.
    1. Wang HY. Investigation of an outbreak of HNANB[E] in Shufu County, Xinjiang. Zhonghua Liu Xing Bing Xue Za Zhi 1989; 10:270–3.
    1. Chau TN, Lai ST, Tse C, et al. . Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 2006; 101:292–6.
    1. Zhu FC, Zhang J, Zhang XF, et al. . Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895–902.
    1. Park SB. Hepatitis E vaccine debuts. Nature 2012; 491:21–2.
    1. Huang S, Zhang X, Jiang H, et al. . Profile of acute infectious markers in sporadic hepatitis E. PLoS One 2010; 5:e13560.
    1. Khuroo MS. Seroepidemiology of a second epidemic of hepatitis E in a population that had recorded first epidemic 30 years before and has been under surveillance since then. Hepatol Int 2010; 4:494–9.
    1. Li RC, Ge SX, Li YP, et al. . Seroprevalence of hepatitis E virus infection, rural Southern People’s Republic of China. Emerg Infect Dis 2006; 12:1682–8.
    1. Zhang J, Li SW, Wu T, et al. . Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Rev Med Virol 2012; 22:339–49.
    1. Zhang J, Zhang XF, Huang SJ, et al. . Long-term efficacy of a hepatitis E vaccine. N Engl J Med 2015; 372:914–22.
    1. Zhang J, Liu CB, Li RC, et al. . Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27:1869–74.
    1. Chen S, Zhou Z, Wei FX, et al. . Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine 2015; 33:4124–9.
    1. Zhang J, Zhang XF, Zhou C, et al. . Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity. Clin Microbiol Infect 2014; 20:O397–405.
    1. Mansuy JM, Bendall R, Legrand-Abravanel F, et al. . Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 2011; 17:2309–12.
    1. Bendall R, Ellis V, Ijaz S, et al. . A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010; 82:799–805.
    1. StataCorp. Stata Statistical Software. Release 11. College Station, TX: StataCorp; 2009.
    1. Katz J, Khatry SK, LeClerq SC, West KP, Christian P. The post-partum mid-upper arm circumference of adolescents is reduced by pregnancy in rural Nepal. Matern Child Nutr 2010; 6:287–95.
    1. Labrique AB, Zaman K, Hossain Z, et al. . An exploratory case control study of risk factors for hepatitis E in rural Bangladesh. PLoS One 2013; 8:e61351.
    1. Teshale EH, Grytdal SP, Howard C, et al. . Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clin Infect Dis 2010; 50:1006–10.
    1. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702–6.
    1. Su Y, Huang S, Guo M, et al. . Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination. Clin Microbiol Infect 2017; 23:336.e4.
    1. Kmush BL, Zaman K, Yunus M, et al. . A ten year immunopersistence study of hepatitis E antibodies in rural Bangladesh. Am J Epidemiol. 2018. doi:10.1093/aje/kwy044. [Epub ahead of print]
    1. Matsubayashi K, Kang JH, Sakata H, et al. . A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008; 48:1368–75.
    1. Hewitt PE, Ijaz S, Brailsford SR, et al. . Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384:1766–73.
    1. Tamura A, Shimizu YK, Tanaka T, et al. . Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007; 37:113–20.
    1. Tuaillon E, Tabaa YA, Petitjean G, et al. . Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods 2006; 315:144–52.
    1. Kulkarni SP, Sharma M, Tripathy AS. Antibody and memory B cell responses in hepatitis E recovered individuals, 1–30 years post hepatitis E virus infection. Sci Rep. 2019; 9:4090 doi:10.1038/s41598-019-40603-9.
    1. Mast EE, Alter MJ, Holland PV, Purcell RH. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology 1998; 27:857–61.
    1. Wenzel JJ, Preiss J, Schemmerer M, et al. . Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis 2013; 207:497–500.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir